about
Epigallocatechin Gallate Nanodelivery Systems for Cancer TherapyDesign and statistical modeling of mannose-decorated dapsone-containing nanoparticles as a strategy of targeting intestinal M-cells.Design of a nanostructured lipid carrier intended to improve the treatment of tuberculosis.Design, development, and characterization of lipid nanocarriers-based epigallocatechin gallate delivery system for preventive and therapeutic supplementation.Treatment of Francisella infections via PLGA- and lipid-based nanoparticle delivery of antibiotics in a zebrafish model.The formulation of nanomedicines for treating tuberculosis.Effects of novel triple-stage antimalarial ionic liquids on lipid membrane models.Therapeutic Potential of Epigallocatechin Gallate Nanodelivery SystemsAntimicrobial properties of membrane-active dodecapeptides derived from MSI-78.Molecular interactions of rifabutin with membrane under acidic conditions.Drug-membrane interaction studies applied to N'-acetyl-rifabutin.Targeted macrophages delivery of rifampicin-loaded lipid nanoparticles to improve tuberculosis treatment.Mannosylated solid lipid nanoparticles for the selective delivery of rifampicin to macrophages.Mucoadhesive chitosan-coated solid lipid nanoparticles for better management of tuberculosis.Folate-targeted nanostructured lipid carriers for enhanced oral delivery of epigallocatechin-3-gallate.Molecular interaction of Rifabutin on model lung surfactant monolayers.A 17-mer Membrane-Active MSI-78 Derivative with Improved Selectivity toward Bacterial Cells.Effect of the alkyl group in the piperazine N-substitution on the therapeutic action of rifamycins: A drug-membrane interaction study.Acylation of the S4-PV cell-penetrating peptide as a means of enhancing its capacity to mediate nucleic acid delivery: Relevance of peptide/lipid interactionsEvaluation of the effect of rifampicin on the biophysical properties of the membranes: Significance for therapeutic and side effectsEffects of a novel antimycobacterial compound on the biophysical properties of a pulmonary surfactant model membraneIn Vitro Assessment of NSAIDs-Membrane Interactions: Significance for Pharmacological ActionsInteractions of N′-acetyl-rifabutin and N′-butanoyl-rifabutin with lipid bilayers: A synchrotron X-ray studyInterplay of mycolic acids, antimycobacterial compounds and pulmonary surfactant membrane: A biophysical approach to diseaseEvaluation of the Structure-Activity Relationship of Rifabutin and Analogs: A Drug-Membrane StudyInsights about α-tocopherol and Trolox interaction with phosphatidylcholine monolayers under peroxidation conditions through Brewster angle microscopyInteractions of isoniazid with membrane models: Implications for drug mechanism of actionAntituberculosis Drug Interactions with Membranes: A Biophysical Approach Applied to BedaquilineEGCG Mediated Targeting of Deregulated Signaling Pathways and Non-Coding RNAs in Different Cancers: Focus on JAK/STAT, Wnt/β-Catenin, TGF/SMAD, NOTCH, SHH/GLI, and TRAIL Mediated Signaling PathwaysAntibiotic interactions using liposomes as model lipid membranesEGCG intestinal absorption and oral bioavailability enhancement using folic acid-functionalized nanostructured lipid carriersOptimization of Rifapentine-Loaded Lipid Nanoparticles Using a Quality-by-Design Strategy
P50
Q26746909-48C4492F-E2AD-428D-A41B-49FB24203861Q37003811-F3C18AB4-6170-4587-8586-129E32DBECC5Q37158892-5F6F31CF-62A4-42B1-BEBA-6B1A10789595Q37395602-E43187D3-825A-4D0E-9CBA-6ACE0E2C73E7Q38719632-023E136C-4285-4C1B-981A-D01FCB1A50F8Q38816020-133411DE-D4BE-40AD-BD6E-924F815C0E05Q40124524-9A9A97F8-A83D-4702-B0CB-95F8E92A4ACBQ41169121-7780F816-BBDD-43AA-A8D9-D833FBA36C24Q41484590-A227897F-2306-4599-AEF2-92B824A8462BQ41579917-2567E53C-6E99-493F-B46C-D1991DB3D1B3Q45836607-B23E651A-E18B-4750-8E0D-965A5C4813CCQ48606369-55CE46D7-A861-43A5-ACAB-EDEF53792E8AQ50058428-F9BCEB04-1EBB-4B8F-8369-E6655C8CF960Q50084819-72563BEF-929A-4E83-858B-DF6C633C5722Q50195683-5CEA186C-2E2A-4645-9DFA-A31AF274F946Q52629152-5EB2F7AA-0904-462B-AA38-C2F35E2B1D3DQ52660908-71BD3F70-092E-4856-8AEC-99673AF3CD52Q54224907-C8600646-FAB6-430F-B57F-C4458DF15A11Q57033900-9E46E687-BD4D-4F63-BC15-C7297543B27CQ59163795-E36675D5-C9AE-4F70-A3A6-E7174B436A3CQ59163800-E65DACE5-509C-453C-A6C3-C82391A229BBQ59163804-6C73EC92-4F81-4FA8-80F0-EA87C860976CQ59163806-21AA0ACD-C643-47A2-9AFA-ED5223E4A636Q61918798-F61D1DBD-4684-4FC1-AAE4-1D12C8F834EEQ62017481-71F8C5D3-E038-4914-A725-7756BAF444E8Q62537174-4F123857-6E28-4D29-B73C-B8511C28A77CQ63201219-4C1A74D0-BEA5-48A2-B0DB-0BBE8A0BFC31Q91037409-4DEB22AC-E399-463A-BAB9-44638B6E3156Q91925281-66DC4213-6923-4EAB-8112-32ADCD855C04Q91948044-D6E2794A-7CB2-4948-AEE3-C26AC2530337Q91976399-FA9BC6AA-B0EB-4ED4-B6C4-57ED811B2AF7Q92811731-2E1F9B8E-F477-4129-927A-3FEB0FA553C0
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Marina Pinheiro
@ast
Marina Pinheiro
@en
Marina Pinheiro
@es
Marina Pinheiro
@nl
Marina Pinheiro
@sl
type
label
Marina Pinheiro
@ast
Marina Pinheiro
@en
Marina Pinheiro
@es
Marina Pinheiro
@nl
Marina Pinheiro
@sl
prefLabel
Marina Pinheiro
@ast
Marina Pinheiro
@en
Marina Pinheiro
@es
Marina Pinheiro
@nl
Marina Pinheiro
@sl
P106
P21
P31
P496
0000-0002-6931-1355